DENVER – The International Association for the Study of Lung Cancer (IASLC) created the 2016 consensus statement on optimizing management of epidermal growth factor receptor (EGFR) mutation positive (M+) non-small cell lung cancer (NSCLC) patients, published in the Journal of Thoracic Oncology (JTO), to discuss key pathologic, diagnostic, and therapeutic considerations. The statement also makes recommendations for clinical guidance and research priorities, such as optimal choice of EGFR tyrosine kinase inhibitors (TKIs), management of brain metastasis, role of re-biopsies, and use of circulating free DNA (cfDNA) for molecular studies.
The FDA recently took an important step to protect public health by publishing a final rule to begin regulating e-cigarettes, cigars, and other tobacco products.
Conversation with Dr. Gilberto Lopez in Conjunction with 2016 Asia Pacific Lung Cancer Conference (APLCC)
One of the most pressing problems in oncology today is the rising costs of cancer treatment. Cancer medication costs in the U.S. have doubled during the last decade: from $5,000 a month to about $10,000-$12,000 per month. One of the reasons for this could be the high costs and time period involved in developing new drugs. “It can take more than 15 years and over $2.8 billion to develop a new drug,” said Dr. Gilberto Lopez, a medical oncologist in Brazil and Chief Medical Officer for the Oncoclinicas Group – the largest oncologists’ group in Latin America with more than 300 physician members. Dr. Lopez is also the Associate Editor of the Journal of Global Oncology.
CHIANG MAI, THAILAND - Lung cancer is the most common cancer worldwide, and especially in the Asian-Pacific region, is a major public health problem. In 2012, there were an estimated 1.8 million new lung cancer cases (13 percent of all cancers diagnosed), and 1.59 million deaths (19.4 percent of the total cancer deaths). Despite many recent advancements in the treatment of lung cancer, there are challenges in the use of novel regimens.
Conversation with Dr. Francoise Mornex and Dr. Punnarerk Thongcharoen in Conjunction with 2016 Asia Pacific Lung Cancer Conference (APLCC)
The treatment of locally advanced non-small cell lung cancer (NSCLC) is becoming a significant challenge because of a growing proportion of patients with unresectable (cannot be operated upon) stage III disease. Despite a multimodality approach consisting of concurrent chemo-radiotherapy, the prognosis remains poor.